B-hCD73 mice_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

Please input keywords

Order

*Country

日本

アメリカ

中国

オーストラリア

シンガポール

イギリス

フランス

ドイツ

スイス

イタリア

カナダ

韓国

オランダ

ベルギー

スウェーデン

その他

*Province

*City

*Name

*Telephone

*Company

*Position

*Email

*Verification code

*Verification Code

Home

動物・細胞モデル

Humanized Mouse Models

Immune-checkpoint Humanized Mice

Text

B-hCD73 mice

Strain Name	C57BL/6-Nt5e^{tm1(NT5E)Bcgen}/Bcgen	Common Name	B-hCD73 mice
Background	C57BL/6	Catalog number	110027
Related Genes	NT5E (Nt5e, 5' nucleotidase, ecto)
NCBI Gene ID	23959

Protein expression analysis

from clipboard

Strain specific CD73 expression analysis in homozygous B-hCD73 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hCD73 (H/H) mice, and analyzed by flow cytometry with species-specific anti-CD73 antibody. Mouse CD73 was detectable in WT mice. Human CD73 was exclusively detectable in homozygous B-hCD73 but not WT mice.

Protein expression analysis

Strain specific CD73 expression analysis in homozygous B-hCD73 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hCD73 (H/H) mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-CD73 antibody. Mouse CD73 was detectable in WT mice. Human CD73 was exclusively detectable in homozygous B-hCD73 but not WT mice.

from clipboard

In vivo efficacy of anti-human CD73 antibodies

from clipboard

Antitumor activity of anti-human CD73 antibodies in B-hCD73 mice. (A) Anti-human CD73 antibodies inhibited hCD73-MC38 tumor growth in B-hCD73 mice. Murine colon cancer hCD73-MC38 cells were subcutaneously implanted into homozygous B-hCD73 mice (female, 6-7 week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm³, at which time they were treated with anti-human CD73 antibodies with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, two anti-human CD73 antibodies (in house) were efficacious in controlling tumor growth in B-hCD73 mice, demonstrating that the B-hCD73 mice provide a powerful preclinical model for in vivo evaluation of anti-human CD73 antibodies. Values are expressed as mean ± SEM.

Combination therapy of mPD-1 Ab and hCD73 Ab

Antitumor activity of anti-mouse PD-1 antibody combined with anti-human CD73 antibody in B-hCD73 mice. (A) Anti-mouse PD-1 antibody combined with anti-human CD73 antibody (provided by client) inhibited hCD73-MC38 tumor growth in B-hCD73 mice. Murine colon cancer hCD73-MC38 cells were subcutaneously implanted into homozygous B-hCD73 mice (female, 7-8 week-old, n=6). Mice were grouped when tumor volume reached approximately 80 mm³, at which time they were treated with anti-mouse PD-1 antibody and anti-human CD73 antibody with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, combination of anti-mPD-1 antibody and anti-hCD73 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hCD73 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of mPD-1 antibodies and hCD73 antibodies. Values are expressed as mean ± SEM.